Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial

The therapeutic potential of phosphodiesterase-5 inhibitor PF-03049423 was evaluated in a phase 2, multicenter, randomized, double-blind, placebo-controlled study of subjects with acute ischemic stroke (Clinical Trial Registration Information: http://www.clinicaltrials.gov, unique identifier: NCT01208233; http://www.clinicaltrialsregister.eu, EudraCT number: 2010-021414-32).

Source: Journal of Stroke and Cerebrovascular Diseases - December 28, 2015 Category: Neurology Authors: Franco Di Cesare, Jessica Mancuso, Phil Woodward, Martin M. Bednar, Peter T. Loudon, A9541004 Stroke Study Group Source Type: research